

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16952CON1CIP3	Application No. 10/726,904
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kei Aoki	
		Filing Date December 2, 2003	Group Art Unit 1654

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1.	4,234,566	11/18/80	Packman et al.			
	2.	4,713,240	12/15/87	Wilkins et al.			
	3.	4,720,494	01/19/88	Felger et al.			
	4.	4,832,936	05/23/89	Holter et al.			
	5.	4,935,969	06/26/90	Farnsworth			
	6.	5,512,547	04/01/1996	Johnson et al.			
	7.	5,714,468	02/01/98	Binder et al.			
	8.	6,306,403	10/23/01	Donovan			
	9.	6,319,505	11/20/01	Aoki et al.			
	10.	6,333,037	12/25/01	Aoki et al.			
	11.	6,372,226	04/16/02	Aoki et al.			
	12.	6,395,277	05/28/02	Graham			
	13.	6,372,226	04/16/02	Aoki et al.			
	14.	6,448,231	09/10/02	Graham			
	15.	6,458,365	10/01/02	Aoki et al.			
	16.	6,500,436	12/31/02	Donovan			
	17.	6,623,742	09/23/03	Voet			
	18.	6,683,049	01/27/04	Aoki et al.			
	19.	6,872,397	03/29/05	Aoki et al.			
	20.	6,887,476	05/03/05	Aoki et al.			
	21.	6,939,852	09/01/05	Graham			
	22.	6,974,578	12/13/05	Aoki et al.			
	23.	6,986,893	01/17/06	Aoki et al.			
	24.	2003/0118598	06/26/03	Hunt			
	25.	2004/0126397	07/01/04	Aoki et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner	Desig.	Document	Publication	Country or	Class	Subclass	Translation
----------	--------	----------	-------------	------------	-------	----------	-------------

Examiner Signature /Anish Gupta/	Date Considered 02/19/2008
-------------------------------------	-------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AG/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16952CON1CIP3	Application No. 10/726,904
		Applicant Kei Aoki	
		Filing Date December 2, 2003	Group Art Unit 1654

**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

							Yes	No
26.	WO94/000081	01/06/94	WO					
27.	WO94/015629	07/21/94	WO					
28.	WO95/017904	07/06/95	WO					
29.	2272697	05/25/94	GB					
30.	19852981	05/28/00	DE					

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	31.	Anderson et al., "Botulinum Toxin Treatment of Spasmodic Torticollis," <u>J. of the Royal Soc. Of Med.</u> , 1992, 85:524-529
	32.	"Athena files US and Canadian Investigational New Drugs," <u>Scrip</u> , June 5, 1992, No. 1724, p. 29
	33.	"Athena Outlines Business Strategy," <u>Marketedletter</u> , Oct. 5, 1992
	34.	Blasl et al., "Botulinum Neurotoxin A Selectively Cleaves the Synaptic Protein SNAP-25," <u>Nature</u> , 1993, 365:160-163
	35.	Berardelli et al., "Botulinum Toxin Treatment in Patients with Focal Dystonia and Hemifacial Spasm. A multicenter study of the Italian Movement Disorder Group," <u>Neurol. Sci.</u> , 1993, 14:361-367
	36.	Bergmann et al., "Selective Degeneration of Sudomotor Fibers in Ross Syndrome and Successful Treatment of Compensatory Hyperhidrosis with Botulinum Toxin," <u>Muscle & Nerve</u> , 1998, 21(12):1790-1793
	37.	Biglan, "Experience with Botulinum A toxin (Oculinum) in the treatment of strabismus," <u>Contemp. Ophth. Forum</u> , 1987, 5(6): 230-240
	38.	Blitzer et al., "Electromyographic Findings in Focal Laryngeal Dystonia (Spastic Dysphonia)," <u>Ann. Otol. Rhinol. Laryngol.</u> , 1985, 94:591-594
	39.	Bodde et al., "Transdermal Peptide Delivery," <u>Biochem. Soc. Trans.</u> , 1989, 17(5): 943-945
	40.	"BOTOX," 2000, 9 pages [web site]
	41.	"Botulinum Toxin for the Treatment of Facial Lines and Wrinkles," 2005, [www.shorelaser.com/BotoxA.html], pp. 1-7
	42.	"Botulinum-Toxin hilft bei Augenleiden," (December 1986)
	43.	"Botulinum Toxin may be useful in a range of muscular disorders," <u>Int. Med. News</u> , 1991, 15:24(16):36
	44.	Borodic et al., "Botulinum B Toxin as an Alternative to Botulinum A Toxin: A Histologic Study," <u>Ophthalm. Plast. Reconstr. Surg.</u> , 1993, 9(3):182-190
	45.	Borodic et al., "Clinical and scientific aspects of botulinum A toxin," <u>Ophthalm Clinics of N. America</u> , 1991, 4(3):491-503
	46.	Boroff et al., "Amino acid analysis of the isolated and purified components from crystalline toxin of Clostridium botulinum type A," <u>Infect. Immun.</u> , 1970, 2(5):679-680
	47.	Brin et al., "Assessment: The clinical usefulness of Botulinum toxin A in treating neurologic disorders," <u>Neurology</u> , 1990, 40: 1332-1336

Examiner Signature	/Anish Gupta/	Date Considered	02/19/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AG/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16952CONICIP3	Application No. 10/726,904
		Applicant Kei Aoki	
		Filing Date December 2, 2003	Group Art Unit 1654
		Information Disclosure Statement by Applicant (Use several sheets if necessary)	

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	48.	Brin et al., "Localized Injections of Botulinum Toxin for the Treatment of Focal Dystonia and Hemifacial Spasm," <u>Advances in Neurology</u> , 1988, 50:599-608
	49.	Buckelew, "Fibromyalgia: a rehabilitation approach. A review.," <u>Am. J. of Phy. Med. & Rehab.</u> , 1989, 68(1):37-42
	50.	Callaway, "Botulinum Toxin Type B: Pharmacology and Biochemistry," <u>Clinics in Dermatology</u> , 2004, 22:23-29
	51.	"Cervical Dystonia" [www.fpnotebook.com/NEU151.htm]; pp. 1-2 (retrieved 09-03-2003)
	52.	Choi et al., "Transdermal delivery of bioactive peptides: the effect of n-decylmethyl sulfoxide, pH, and inhibitors on Enkephalin metabolism and transport," <u>Pharm. Res.</u> , 1990, 7(11): 1099-1106
	53.	Cioffi et al., "Microvasculature of the Anterior Optic Nerve," <u>Surv. Of Ophthal.</u> , 1994, 38: S107-S116
	54.	Cohen et al., "Treatment of Focal Dystonias of the Hand with Botulinum Toxin Injection" <u>Neurology</u> , 1987, 37:123-124
	55.	Clark, "Cervical Dystonia Following Exposure to High-G Forces," <u>Aviat. Space Environ. Me.</u> , 1990, 61: 935-937
	56.	Cosgrove et al., "Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse model," <u>Dev. Med. And Child Neurol.</u> , 1994, 36: 379-385
	57.	Cosgrove et al., "Botulinum toxin in the management of lower limb in cerebral palsy," <u>Dev. Med. And Child Neurol.</u> , 1994, 36: 386-396
	58.	Dasgupta et al., "Purification of Clostridium botulinum type A toxin, Biochimica," <u>Biochim. Biophys. Acta.</u> , 1970, 214(2):343-349
	59.	Dasgupta et al., "Role of a protease in natural activation of Clostridium botulinum neurotoxin," <u>Infect. Immun.</u> , 1972, 6(4):587-590
	60.	Dasgupta et al., "Separation of toxin and Hemagglutinin from crystalline toxin of Clostridium botulinum type A by anion exchange chromatography and determination of their dimensions by gel filtration," <u>J. Biol. Chem.</u> , 1969, 243(5):1065-1072
	61.	Dasgupta, "The Structure of Botulinum Neurotoxin," <u>Botulinum Neurotoxin and Tetanus Toxin</u> , 1989, pp. 53-67
	62.	Davis et al., "Significant Improvement of Stiff-Person Syndrome After Paraspinal Injection of Botulinum Toxin A," <u>Movement Disorders</u> , 1993, 8(3):371-373
	63.	Departments, Programs and Services [www.gillettechildren.org/about-us/staff/departments.html]
	64.	Duane, "Spasmodic Torticollis," <u>Adv. Neuro.</u> , 1988, 49: 135-150
	65.	Dunn et al., <u>Ophthal.</u> , 1986, 93(4): 470-475
	66.	Eames et al., "The effect of Botulinum toxin A on gastrocnemius length: magnitude and duration of response," <u>Dev. Med and Child Neurol.</u> , 1999, 41: 226-232
	67.	"Elan Pharmaceuticals exploring potential use of MYOBLOC (Botulinum Toxin Type B) in Spasticity, Pain and Cermaticolic Applications," [www.biospace.com/news_story.cfm?StoryID=4964504&full=1]
	68.	Elston et al., "Paralytic Strabismus: The Role of Botulinum Toxin," <u>Br. J. Ophthalmol.</u> , 1985, 69(12):891-896.
	69.	Elston, "Thyroid Eye Disease," <u>Eye</u> , 1990, 4(pt. 4):vii

Examiner Signature /Anish Gupta/	Date Considered 02/19/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AG/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16952CON1CIP3	Application No. 10/726,904
		Applicant Kei Aoki	
		Filing Date December 2, 2003	Group Art Unit 1654
		Information Disclosure Statement by Applicant (Use several sheets if necessary)	

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	70.	"Enzyme Linked Immuno Sorbent Assays (ELISAs) to Detect Botulinum Toxins Using high Titer-Rabbit Anti-Sera," <u>Botulinum and Tetanus Neurotoxins</u> , 1993, Plenum Press
	71.	Escobar et al., "Myofascial Pain Syndrome," <u>Orth. Review</u> , 1987, 16(10):708-713
	72.	Eustis et al., "Botulinum Toxin," <u>Ophthalm. Clinics of N. Am.</u> , 1989, 2(1): 163-172
	73.	Gammon et al., "Botulinum chemodenervation treatment of strabismus," <u>J. Ped. Ophthalm. S.</u> , 1989, 96(7): 931-934
	74.	Gjerstad et al., "Treatment of Focal Dystonia with Botulinum Toxin," <u>Tidsskrift for Den Norske Laegeforening</u> , 1991, 111(21):2637-2639
	75.	Glogau, "Botulinum A Neurotoxin for Axillary Hyperhidrosis," <u>Dermatol. Surg.</u> , 1998, 24(8):817-819
	76.	Goodnough et al., "Stabilization of Botulinum Toxin Type A During Lyophilization," <u>Applied and Environmental Microbiology</u> , 1992, 58(10):3426-3428
	77.	Greene et al., "Use of Botulinum Toxin Type F Injection to Treat Torticollis in Patients with Immunity of Botulinum Toxin Type A," <u>Movement Disorders</u> , 1994, 8(4): 479-483
	78.	Grusser, "Die ersten systematischen Beschreibungen und tierexperimentellen Untersuchungen des Botulismus," <u>Sudhoff's Arch.</u> , 1986, 70(2): 167-186
	79.	Henesen, "Deadly toxin calms excited muscles," <u>New Scientist</u> , 1990, New Science Publications, London, GB, No. 1746, p. 24
	80.	Humphry, "Botulinum Toxin: A New Ally of an old adversary," <u>BMJ</u> , 1989, 298:136-137
	81.	Jankovic et al., "Botulinum A toxin for cranial-cervical dystonia: A double-blind, placebo-controlled study," <u>Neurology</u> , 1987, 37:616-623
	82.	Jankovic et al., "Therapy with Botulinum Toxin," 1994, Marcel Dekker, Inc., p. 76
	83.	Jedynak et al., "Treatment of spasmodic torticollis by local injections of Botulinum toxin," <u>Rev. Neurol.</u> , 1990, 146:440-443
	84.	Jost et al., "Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX(R)) in healthy volunteers," <u>J. Neurol. Transm.</u> , 2005, 112: 905-913
	85.	Kaszynski et al., "Mouse Foot Screen for the Inhibition of Sweating by Anticholinergic Drugs," <u>The J. of Investi. Derma.</u> , 1974, 62:510-513
	86.	Kerner, "Das Fettgift oder die fettsaure und ihre wirkungen auf den thierischen organismus, ein beytrag zur untersuchung des in verdorbenen wursten giftig wirkenden stoffes," <u>Stuttgart und Tubingen: Cotta</u> , 386 pages
	87.	Knight, "Botulinum Toxin Types A, B and D Inhibit Catecholamine Secretion from Bovine Adrenal Medullary Cells," <u>FEBS. Lett.</u> , 1986, 207(2): 222-226
	88.	Kondo et al., "Modification of the action of pentagastrin on acid secretion by Botulinum toxin" <u>Experientia</u> , 1977, 33(6):750-751
	89.	Lewis, "Wrinkles in Motion the Ultimate Guide," 2002 [website]
	90.	Liedtke et al., "Transdermal administration of insulin in type II diabetes, Results of a clinical pilot study," <u>Arzneimittelforschung</u> , 1990, 40(8): 884-886
	91.	Magoon, <u>Ophthalm.</u> , 1989, 96(7): 931-934
	92.	Magoon, "Botulinum Toxin chemo-denervation for strabismus in infants and children," <u>J. Ped. Ophthalm. S.</u> , 1984, 21(3): 110-113
	93.	Melling et al., <u>Eye</u> , 1988, 2:16-23

Examiner Signature /Anish Gupta/	Date Considered 02/19/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AG/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16952CON1CIP3	Application No. 10/726,904
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kei Aoki	
		Filing Date December 2, 2003	Group Art Unit 1654
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	94.	Mezaki et al., "Combined use of Type A and F Botulinum Toxins for Blepharospasm: A Double-Blind Control Trial," <u>Movement Disorders</u> , 1999, 14(6):1017-1020
	95.	Naumann et al., "Botulinum Toxin for Focal Hyperhidrosis: Technical Considerations and Improvements in Application," <u>Brit. J. of Derm.</u> , 1998, 139:1123-1124
	96.	Naumann et al., "Botulinum Toxin for Palmar Hyperhidrosis," <u>Lancet</u> , 1997, 349(9047):252
	97.	Naumann et al., "Focal Hyperhidrosis," <u>Arch. Dermatol.</u> , 1998, 134:301-304
	98.	Naver et al., "The Treatment of Focal Hyperhidrosis with Botulinum Toxin," <u>The Eur. J. of Neur.</u> , 1997, 4(2):S75-S79
	99.	News Publication: "Marketing Approvals," <u>Med. World News</u> , 1990, 31(5): 2
	100.	News Publication: "Porton launches Dysport in UK," <u>Scrip</u> , 1991, 1607: 23
	101.	News Publication: "U.S. Food & Drug Administration approves coulinum for strabismus in patients 12 years of age and above and for blepharospasm," <u>Bin. Vis. Quart.</u> , 1990, 5(2): 61
	102.	Odderson, "Axillary Hyperhidrosis: Treatment with Botulinum Toxin A," <u>Arch. Phys. Med. Rehab.</u> , 1998, 79:350-352
	103.	Overmyer, "Botulinum Toxin: Poison with a purpose" <u>Mod. Med.</u> , 1991, 59: 112-116
	104.	Park et al., "Binding of Clostridium Botulinum type B toxin to rat brain synaptosome," <u>Fems. Micro. Lett.</u> , 1990, 60(3): 243-247
	105.	Pope, "Approval Unwrinkles Elan's Brow," http://www.ideaadvisor.com/company/article.asp?aid=7368
	106.	Poewe et al., "Experience with Botulinum Toxin in Cervical Dystonia; Therapy with Botulinum Toxin," 1994, pp. 267-278
	107.	Rader, "Biopharmaceutical Products in the U.S. Market," <u>Biopharma</u> , 2001, 332:271-274
	108.	Reichl et al., "Hyperesthesia Associated with Hyperextension Injuries of the Neck," <u>Injury</u> , 18(4): 234
	109.	Roggenkamper et al., "Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm," <u>J. Neurol. Transm.</u> , 2006, 113: 303-312
	110.	Rosenbaum et al., "Verical rectus muscle transposition and Botulinum Toxin (Oculinum) to medical rectus for abducens palsy," <u>Arch. Ophthalmol.</u> , 1989, 107(6): 820-823
	111.	Sanchez et al., "Propiedades Farmacologicas y Usos Terapeuticos de la Toxina Botulinica," <u>Farmacia Clinica</u> , 1992, 9(5):404-413
	112.	Sanders et al., "Drug delivery systems and routes of administration of peptide and protein drugs," <u>Eur. J. of Drug. Met. And Pharmacol.</u> , 1990, 12(2): 95-102
	113.	Sasaki et al., "Effect of pyrrolidone derivatives on lipid membrane and protein conformation as transdermal penetration enhancer," <u>J. Pharmacobio-Dyn.</u> , 1990, 13: 468-474
	114.	Sato et al., "Purification and some properties of a proteinase and an esterase released from Clostridium Botulinum A, B, and F types," <u>Nippon Saik. Zasshi</u> , 1973, 28(4): 367-374
	115.	Savino et al., "Hemifacial Spasm treated with Botulinum A toxin injection," <u>Arch. Ophthalmol.</u> , 1985, 103(9):1305-1306
	116.	Schantz, "Use of crystalline type A botulinum toxin in medical research," <u>Biomedical aspects of botulism</u> , 1981, Academic Press, New York, pp. 143-150
	117.	Schiavo et al., "Botulinum Neurotoxins are Zinc Proteins," <u>J. Biol. Chem.</u> , 1992, 267(33):23479-23483

Examiner Signature /Anish Gupta/	Date Considered 02/19/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16952CONICIP3	Application No. 10/726,904
	Applicant Kei Aoki		
	Filing Date December 2, 2003	Group Art Unit 1654	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	118.	Schnider et al., "Double-Blind Trial of Botulinum A Toxin for the Treatment of Focal Hyperhidrosis of the Palms," <u>Brit. J. of Derma.</u> , 1997, 136(4):548-552
	119.	Schwartz, "Circulatory Defects of the Optic Disk and Retina in Ocular Hypertension and High Pressure Open Angle Glaucoma," <u>Survey of Ophthal.</u> , 1994, 38
	120.	Scott, "Botulinum Toxin Treatment of Strabismus and Blepharospasm, a multiple investigator study," <u>Proceedings of the 5th meeting of the international strabismological association</u> , 1986, 483-485
	121.	Scott, "Vol VII Module 12: Botulinum Toxin treatment of strabismus," <u>Am. Aca. Ophthal.</u> , 1989, 2:1-11
	122.	Scott et al., <u>Ophthal.</u> , 1985, 92(5): 676-683
	123.	Scott et al., "Botulinum treatment of strabismus in children," <u>Trans. Am. Ophthal. Soc.</u> , 1990, 87: 174-180, 180-184
	124.	Shelley et al., "Botulinum Toxin Therapy for Palmar Hyperhidrosis," <u>J. of Am. Acad. Of Derma.</u> , 1998, 32:227-229
	125.	Simpson, "Current Concepts of the Mechanism of Action of Clostridial Neurotoxins," <u>Botulinum and Tetanus Neurotoxins</u> , 1993, Plenum Press, New York, pp. 1-15
	126.	Simpson, "The Origin Structure and Pharmacological Activity of Botulinum Toxin," <u>Pharmacol. Reviews</u> , 1981, 33(3):155-188
	127.	Simpson, "Clinically Relevant Aspects of the Mechanism of Action of Botulinum Neurotoxin," <u>Journal of Voice</u> , 1992, 6(4):358-364
	128.	Simons, "Fibrositis/fibromyalgia: a form of myofascial trigger points?," <u>Am. J. of Med.</u> , 1986, 81(3A):93-98
	129.	Snow et al., "Treatment of Spasticity with Botulinum Toxin: A Double-Blind Study" <u>Annals of Neurology</u> , 1990, 28(4):512-515
	130.	Southern Utah Spine & Rehabilitation Special Treatment and Tests [http://physical-medicine.net/special.htm]
	131.	Srinivisan et al., "Iontophoresis of polypeptides: effect of ethanol pretreatment of human skin," <u>J. Pharma. Sci.</u> , 1990, 79(7)
	132.	Stacy et al., "Efficacy of Botulinum toxin type B for treatment of blepharospasm: Report of two cases," <u>Naunyn-Schmiedeberg's Archives of Pharmacology</u> , 2002, 365(2):R44
	133.	Stevens et al., "Development and Properties of the secretory response in rat sweat glands: Relationship to the induction of cholinergic function in sweat gland innervation," <u>Dev. Bio.</u> , 1987, 123:179-190
	134.	Tonneson et al., "A double blind trial of a 16-hour transdermal nicotine patch in smoking cessation," <u>New Eng. J. Med.</u> , 1991, 325(5): 311-315
	135.	Tsui et al., "Botulinum Toxin Type B in the Treatment of Cervical Dystonia: A Pilot Study," <u>Neurology</u> , 1995, 45(11):2109-2110
	136.	Verhoef et al., "Transport of peptide and protein drugs across biological membranes," <u>Eur. J. Drug Metab.</u> , 1990, 15(2): 83-93
	137.	Wagman et al., "Botulinum Type A toxin: properties of a toxic dissociation product," <u>Arch. Biochem. Biophys.</u> , 1953, 45:375-383
	138.	Wright et al., "The Spastic Mouse and the search for an animal model of spasticity in human beings," <u>Clin. Orth. And Related Res.</u> , 1990, 253: 12-19

Examiner Signature /Anish Gupta/	Date Considered 02/19/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16952CON1CIP3	Application No. 10/726,904
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kei Aoki	
		Filing Date December 2, 2003	Group Art Unit 1654
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	139.	Yakovleff et al., "Indications and use of botulinic toxin in the treatment of spasticity," <u>Annales de Re. et de Med. Phy.</u> , 1994, 36(5):359-363
	140.	"The Merck Manual of Diagnosis and Therapy," 1987, pp. 1420-1421, 1449-1551
	141.	National Institutes of Health, "Clinical Use of Botulinum Toxin, Consensus Development Conference Statement," Nov. 12-14, 1990, http://consensus.nih.gov/1990/1990BotulinumToxin083html.htm , pp. 1-18

Examiner Signature /Anish Gupta/	Date Considered 02/19/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AG/